Start the conversation
We totally agree.
In fact, we shared the same prediction with you ... in early January.
In that report, we told you that the five top Big Pharma companies alone had $70 billion in cash on hand - and would be looking to use at least some of it to avoid a plunge over the "patent cliff."
If you've acted on our biotech recommendations, you know this sector has been hot for more than a year.
But it could get even hotter.
This heightened M&A potential is bullish for biotech shares: The mere fact that companies are shopping can push up prices for all companies - and it increases the odds of a massive windfall gain if the company you've invested in becomes a buyout target.
Moody's sees it the same way. In addition to the hefty war chest of cash, Moody's researchers listed five reasons that buyouts would increase. Buyouts will escalate because:
This is premium content for Private Briefing subscribers only.